Comparative efficacy of mono- and combined therapy for idiopathic short stature with delayed puberty

• Main Authors: G.N. Rakhimova, K.N. Gilyazetdinov
• Format: Article
• Language: English
• Published: Publishing House Zaslavsky 2018-04-01
• Series: Mìžnarodnij Endokrinologìčnij Žurnal
• Subjects: idiopathic short stature; recombinant growth hormone; growth velocity
• Online Access: http://iej.zaslavsky.com.ua/article/view/136420

Background. Growth hormone therapy for idio­pathic short stature (ISS) is a subject of debate, because of the heterogeneous endocrine profile in these children. The purpose of this work was to evaluate the effectiveness of mono- (testosterone enanthate) and combined therapy (testosterone enanthate and recombinant growth hormone) in adolescents with idiopathic short stature. Materials and methods. The examined youths of Uzbek population (n = 46) with constitutional delay in growth and puberty aged 14.8–16.2 years were divided into three groups in accordance with the type of treatment. Results. It was found that recombinant growth hormone (somatropin) therapy (0.033 mg/kg/day) in combination with testosterone enanthate (50 mg once eve­ry 21 days) is effective and increases the rate of growth in idiopathic short stature with delayed puberty. Conclusions. Monotherapy with testosterone enanthate at a low dose significantly increases the rate of growth in boys with constitutional delay in growth and puberty, compared with the group without treatment, but is significantly less effective than in the group of combined therapy.